Decibel Cannabis Past Earnings Performance
Past criteria checks 0/6
Decibel Cannabis has been growing earnings at an average annual rate of 36.5%, while the Pharmaceuticals industry saw earnings growing at 45.6% annually. Revenues have been growing at an average rate of 39.6% per year.
Key information
36.5%
Earnings growth rate
60.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 39.6% |
| Return on equity | -3.0% |
| Net Margin | -1.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Investors Don't See Light At End Of Decibel Cannabis Company Inc.'s (CVE:DB) Tunnel And Push Stock Down 29%
Oct 13
Decibel Cannabis Company Inc. (CVE:DB) Stock's 33% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 15Decibel Cannabis (CVE:DB) Takes On Some Risk With Its Use Of Debt
Jul 27Decibel Cannabis Company Inc. (CVE:DB) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Jun 02Sentiment Still Eluding Decibel Cannabis Company Inc. (CVE:DB)
Mar 06Here's Why Decibel Cannabis (CVE:DB) Is Weighed Down By Its Debt Load
Jan 10We Think Decibel Cannabis (CVE:DB) Is Taking Some Risk With Its Debt
Sep 28Cautious Investors Not Rewarding Decibel Cannabis Company Inc.'s (CVE:DB) Performance Completely
Jul 15Is Decibel Cannabis (CVE:DB) Using Debt Sensibly?
May 17Decibel Cannabis (CVE:DB) Has Debt But No Earnings; Should You Worry?
Nov 11Decibel Cannabis (CVE:DB) Use Of Debt Could Be Considered Risky
Jul 22Does Decibel Cannabis (CVE:DB) Have A Healthy Balance Sheet?
Nov 24Here's Why Decibel Cannabis (CVE:DB) Has A Meaningful Debt Burden
Aug 21Would Decibel Cannabis (CVE:DB) Be Better Off With Less Debt?
Apr 16Revenue & Expenses Breakdown
How Decibel Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 102 | -1 | 35 | 0 |
| 30 Jun 24 | 106 | 0 | 34 | 0 |
| 31 Mar 24 | 112 | -1 | 34 | 0 |
| 31 Dec 23 | 116 | -2 | 35 | 0 |
| 30 Sep 23 | 107 | -4 | 30 | 0 |
| 30 Jun 23 | 98 | 1 | 27 | 0 |
| 31 Mar 23 | 88 | -1 | 25 | 0 |
| 31 Dec 22 | 79 | -4 | 23 | 0 |
| 30 Sep 22 | 68 | -1 | 21 | 0 |
| 30 Jun 22 | 63 | -7 | 20 | 0 |
| 31 Mar 22 | 56 | -5 | 20 | 0 |
| 31 Dec 21 | 52 | 2 | 18 | 0 |
| 30 Sep 21 | 50 | -1 | 17 | 0 |
| 30 Jun 21 | 44 | -1 | 17 | 0 |
| 31 Mar 21 | 38 | -3 | 14 | 0 |
| 31 Dec 20 | 30 | -9 | 15 | 0 |
| 30 Sep 20 | 20 | -14 | 13 | 0 |
| 30 Jun 20 | 15 | -13 | 11 | 0 |
| 31 Mar 20 | 11 | -9 | 9 | 0 |
| 31 Dec 19 | 6 | -7 | 5 | 0 |
| 30 Sep 19 | 5 | -1 | 3 | 0 |
| 30 Jun 19 | 2 | -1 | 2 | 0 |
| 31 Mar 19 | 1 | -3 | 2 | 0 |
| 31 Dec 18 | 0 | -3 | 2 | 0 |
Quality Earnings: DB is currently unprofitable.
Growing Profit Margin: DB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DB is unprofitable, but has reduced losses over the past 5 years at a rate of 36.5% per year.
Accelerating Growth: Unable to compare DB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: DB has a negative Return on Equity (-3.01%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:34 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Decibel Cannabis Company Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Frederico Yokota Choucair Gomes | ATB Capital Markets |
| Kimberly Thompson-Hedlin | Canaccord Genuity |
| Jenny Wang | Eight Capital |